Total Testosterone Range: Normal Levels, Lab Interpretation, and TRT Monitoring

What Is the Normal Total Testosterone Range for Men?

The American Urological Association (AUA) defines male hypogonadism as a total serum testosterone below 300 ng/dL confirmed on two separate morning specimens. [1] Most reference laboratories report the adult male range as 300, 1 to 000 ng/dL, though some place the upper bound at 1 to 100 ng/dL. A single low result is not enough; testosterone follows a diurnal rhythm, peaking between 7 and 10 a.m. and dropping 25 to 35% by afternoon. [2]

The Endocrine Society's 2018 Clinical Practice Guideline states: "We suggest measurement of morning total testosterone concentration by an accurate and precise assay as the initial diagnostic test." [3] That language is deliberate. Not every lab uses an equally accurate assay. Many community hospitals rely on immunoassay platforms that can underestimate testosterone by 10 to 20% compared with liquid chromatography-tandem mass spectrometry (LC-MS/MS), the gold-standard method endorsed by the CDC Hormone Standardization Program. [4]

Age adds another layer of complexity. A 65-year-old man with a total testosterone of 320 ng/dL sits at the low end of the reference range but may be symptomatic, while a 30-year-old at the same number almost certainly warrants further evaluation. The 2018 Endocrine Society guideline recommends against using age-specific reference ranges specifically because symptom burden, not just the number, should drive treatment decisions. [3]

Practically speaking, clinicians at HealthRX draw total testosterone alongside SHBG (sex hormone-binding globulin) on the same specimen so that free testosterone can be calculated immediately without a second blood draw.

How Free Testosterone Is Calculated and Why It Matters

Free testosterone represents the fraction of total testosterone that is not bound to SHBG or albumin and is therefore immediately bioavailable to androgen receptors in muscle, bone, and brain tissue. Direct free testosterone immunoassays are notoriously unreliable. The preferred approach is calculation using the Vermeulen equation, which takes total testosterone, SHBG, and albumin (assumed 4.3 g/dL) as inputs. [5]

The math matters because two men can have identical total testosterone of 450 ng/dL yet radically different free testosterone. A man with SHBG of 60 nmol/L will have roughly half the free testosterone of a man with SHBG of 20 nmol/L at the same total level. Conditions that raise SHBG include aging, hyperthyroidism, hepatic cirrhosis, and certain anticonvulsants. Obesity and insulin resistance tend to suppress SHBG, which temporarily raises free T even when total T is borderline low.

Reference ranges for calculated free testosterone vary by method, but most labs report normal adult male values between 5.0 and 21.0 ng/dL (50, 210 pg/mL). [5] Symptoms of hypogonadism in the setting of a low or low-normal free T, even with a total T above 300 ng/dL, may justify a clinical conversation about TRT under the right diagnostic framework.

The HealthRX clinical team uses a three-tier evaluation: total testosterone, calculated free testosterone via Vermeulen, and symptom score (AMS scale or ADAM questionnaire). A patient must meet at least two of the three criteria before TRT is initiated. This avoids over-treating men with low numbers but no functional impairment and avoids under-treating symptomatic men with borderline labs.

Estradiol and the Sensitive Assay Requirement

Estradiol (E2) is not just a female hormone. Men convert testosterone to estradiol through the aromatase enzyme, primarily in adipose tissue. On TRT, supraphysiologic estradiol produces symptoms including gynecomastia, water retention, mood instability, and reduced libido, while estradiol that is too low causes joint pain, poor bone density, and low libido. The therapeutic window is narrow: 20, 40 pg/mL is the range most TRT-experienced clinicians target. [6]

The assay type is not optional. Standard immunoassay estradiol tests (labeled "estradiol" without further qualification) were validated for the high estradiol concentrations seen in women. At the lower male range, cross-reactivity with other steroids inflates results by as much as 30%. [7] The correct order is "estradiol, sensitive" or "estradiol, LC-MS/MS." Quest Diagnostics labels this test as Estradiol, Sensitive (#30289); LabCorp uses Estradiol, LC/MS (#140244). Ordering the wrong assay is a common and correctable error.

A 2014 study published in the Journal of Clinical Endocrinology and Metabolism (N=3,690 men) found that estradiol measured by LC-MS/MS was a stronger predictor of sexual dysfunction and bone loss in men than estradiol measured by standard immunoassay, underscoring why assay selection changes clinical decisions. [7]

Aromatase inhibitors such as anastrozole (0.25 to 0.5 mg twice weekly) or exemestane (12.5 mg twice weekly) are sometimes added to TRT protocols when estradiol consistently exceeds 40 pg/mL despite optimized testosterone dosing. Their use is off-label in men and should be guided by symptoms plus confirmatory LC-MS/MS results, not immunoassay numbers alone. [6]

CBC on TRT: Monitoring Hematocrit and Erythrocytosis

Testosterone stimulates erythropoiesis through EPO-dependent and EPO-independent pathways. The result is a predictable rise in red blood cell mass, hemoglobin, and hematocrit. For most men, this is mild and clinically benign. For a subset, hematocrit climbs above 54%, at which point blood viscosity increases enough to raise thromboembolic risk. [3]

The Endocrine Society 2018 guideline states: "We recommend checking hematocrit at baseline, at 3 to 6 months, and then annually. We recommend withholding testosterone therapy if hematocrit is greater than 54%." [3] That threshold is not arbitrary; it aligns with the altitude medicine literature on polycythemia and is consistent with FDA labeling for testosterone products. [8]

In the TRAVERSE trial (N=5,246 men aged 45, 80 with hypogonadism and cardiovascular risk factors), cardiovascular event rates at a median 33 months were non-inferior for testosterone vs. placebo, but the testosterone group showed a statistically higher incidence of pulmonary embolism (0.9% vs. 0.5%, P<0.05) and deep vein thrombosis. [9] CBC monitoring specifically targets the erythrocytosis mechanism that contributes to this finding.

Practical management when hematocrit exceeds 54% involves:

1. Hold TRT until hematocrit drops below 50%.
2. Reduce dose or extend the injection interval.
3. Switch delivery method. Transdermal testosterone produces smaller hematocrit increases than intramuscular injection because it avoids the supraphysiologic peaks seen after injection. [10]
4. Therapeutic phlebotomy is a last resort and should not become routine practice to "allow" continuation of a dose that is simply too high.

A baseline CBC before TRT is non-negotiable. Men who enter therapy with hematocrit already at 48 to 50% (common in smokers and men with sleep apnea) reach the 54% threshold quickly and need more frequent monitoring, typically every 6 to 8 weeks for the first six months.

Lipid Panel on TRT: What the Data Actually Show

The relationship between testosterone and lipid profiles is more nuanced than early headlines suggested. Testosterone replacement can modestly reduce HDL cholesterol, particularly with oral or injected forms, while its effects on LDL and triglycerides are variable and often modest. [11]

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, reported that over 33 months, testosterone-treated men had a mean HDL decrease of approximately 2.8 mg/dL compared with placebo. [9] That is statistically significant but of uncertain clinical magnitude in isolation. LDL changes were not clinically meaningful in the same trial.

The Endocrine Society guideline recommends a lipid panel at baseline, at 3 to 6 months after TRT initiation, and annually thereafter. [3] If a patient is already on a statin, the baseline lipid panel helps distinguish testosterone-related changes from statin effects during follow-up.

Oral testosterone undecanoate (Jatenzo, FDA-approved 2019) carries a specific FDA label warning about increased cardiovascular risk attributed partly to HDL reduction, which averaged 22% in its key trials. [12] Injectable testosterone cypionate and enanthate, the most commonly prescribed forms in U.S. TRT, show smaller and more variable effects on HDL. Transdermal gels (AndroGel, Testim, Vogelxo) generally produce minimal lipid changes at standard doses.

Men with pre-existing dyslipidemia should have a lipid panel at 6 weeks after starting or adjusting TRT, not at the 3-month mark, because HDL shifts can appear early and inform aromatase inhibitor or statin adjustments. This is a clinical nuance rarely captured in guideline tables.

LH and FSH: Why You Still Need Them Before Starting TRT

Before attributing low testosterone to primary or secondary hypogonadism, a clinician needs luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These two pituitary hormones classify the etiology, which changes management entirely.

Primary hypogonadism (testicular failure) produces low testosterone with high LH and FSH. Secondary or hypogonadotropic hypogonadism produces low testosterone with low or normal LH and FSH. A 40-year-old man with low testosterone, suppressed LH, and high prolactin needs pituitary MRI and prolactin management before TRT is appropriate. Handing him testosterone without checking LH/FSH is a diagnostic error that delays identifying a pituitary adenoma.

Once TRT begins, LH and FSH fall to near zero because exogenous testosterone suppresses the hypothalamic-pituitary axis. At that point, measuring LH and FSH on-therapy is not clinically useful unless fertility preservation with hCG (human chorionic gonadotropin) is part of the plan. Men who want to maintain spermatogenesis require concurrent hCG (typically 500, 1 to 500 IU subcutaneously two to three times weekly) or a transition to clomiphene citrate, both of which preserve LH signaling to the testes. [13]

PSA, Metabolic Panel, and Vitamin D: The Supporting Cast

A prostate-specific antigen (PSA) measurement at baseline is required before TRT in men over 40, per the AUA 2018 guideline, because testosterone can accelerate growth of occult prostate cancer. [1] PSA should be re-checked at 3 to 6 months. A rise of more than 1.4 ng/mL above baseline in any 12-month period, or an absolute PSA above 4.0 ng/mL, warrants urology referral before TRT continues. [1]

A comprehensive metabolic panel (CMP) checks hepatic function, renal function, and fasting glucose. Testosterone has modest insulin-sensitizing effects; men with type 2 diabetes on TRT may need antihyperglycemic medication adjustments, and the Endocrine Society recommends glucose monitoring in this population. [3]

Vitamin D (25-OH vitamin D) is worth measuring once at baseline. Deficiency, defined as a level below 20 ng/mL by the Endocrine Society, is associated with lower SHBG and lower total testosterone in cross-sectional data. [14] Correcting vitamin D to 40 to 60 ng/mL is inexpensive and may modestly support endogenous testosterone production in deficient men, though it does not substitute for TRT when hypogonadism is confirmed.

How to Interpret Labs While on TRT: Timing and Context

Lab results drawn at the wrong time relative to dosing are misleading. The correct timing depends on the delivery method.

For weekly intramuscular or subcutaneous testosterone cypionate or enanthate injections, draw the specimen at trough, meaning the morning of the injection day before the dose is given. Trough total T should generally fall between 500 and 700 ng/dL in most TRT protocols, with peaks 24 to 48 hours post-injection reaching 800, 1 to 100 ng/dL. Drawing at peak instead of trough will falsely inflate the number and may prompt unnecessary dose reductions.

For daily transdermal gels or creams, draw 4 to 8 hours after application. The pharmacokinetics of transdermal delivery are flatter, so timing matters less, but morning post-application draws are most reproducible.

For testosterone pellets (implanted subcutaneously, lasting 3 to 6 months), draw at mid-cycle, roughly 6 weeks after insertion, to capture the plateau phase rather than the early peak or late trough.

Estradiol and CBC should follow the same timing as testosterone to ensure all values reflect the same hormonal state. Mixing a trough testosterone with a peak-phase estradiol from a different day produces a clinically uninterpretable snapshot.

Putting the Lab Panel Together: A Full TRT Monitoring Schedule

A coherent monitoring schedule prevents both under-surveillance and unnecessary testing. The HealthRX clinical team uses the following structure:

Before TRT initiation: Total testosterone (two morning draws on separate days), free testosterone (calculated via SHBG and albumin), LH, FSH, estradiol sensitive (LC-MS/MS), prolactin, CBC with differential, CMP, lipid panel, PSA (men over 40), thyroid-stimulating hormone (TSH), and 25-OH vitamin D.

At 6 to 8 weeks after initiation or dose change: Total testosterone (trough), estradiol sensitive, hematocrit (or full CBC if baseline was borderline), and PSA if recently started.

At 3 to 6 months: Full panel: total testosterone, free testosterone (calculated), estradiol sensitive, CBC, lipid panel, CMP, PSA.

Annually (stable patients): All of the above, plus DXA bone density every 1 to 2 years in men with baseline osteopenia or osteoporosis per the Endocrine Society guideline. [3]

This schedule aligns with both the Endocrine Society 2018 guideline and the AUA 2018 guideline recommendations, synthesized into a single clinical workflow. [1,3]

The single most common monitoring error seen in community TRT practice is checking only total testosterone and ignoring estradiol, CBC, and lipid panels after the first year of treatment. Stable symptoms do not equal stable labs. Hematocrit can drift upward slowly over 18 to 24 months without producing noticeable symptoms until it crosses 54%.